Phase II Trial of Adjuvant Immunotherapy with Autologous Tumor-derived Gp96 Vaccination in Patients with Gastric Cancer

Conclusion: gp96 vaccination elicits tumor-specific immune responses and can be safely used in adjuvant settings combined with chemotherapy. Patients with less-aggressive diseases might benefit from gp96 therapy.

Source: Journal of Cancer - September 12, 2017 Category: Cancer & Oncology Authors: Kecheng Zhang, Zheng Peng, Xiaohui Huang, Zhi Qiao, Xinxin Wang, Ning Wang, Hongqing Xi, Jianxin Cui, Yunhe Gao, Xijian Huang, Hua Gao, Bo Wei, Lin Chen Tags: Research Paper Source Type: research